Literature DB >> 25054350

Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?

Marc C Chamberlain1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 25054350      PMCID： PMC6169456          DOI： 10.2217/cns.12.38

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  27 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia L Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa M DeAngelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard Kaplan; Anthony J Murgo; Charles Stiles; Michael D Prados
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

3.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.

Authors:  H B Newton; S R Scott; C Volpi
Journal:  Br J Neurosurg       Date:  2004-10       Impact factor: 1.596

4.  Treatment of high risk or recurrent meningiomas with hydroxyurea.

Authors:  Mark A Rosenthal; David L Ashley; Lawrence Cher
Journal:  J Clin Neurosci       Date:  2002-03       Impact factor: 1.961

5.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 6.  The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.

Authors:  Marc C Chamberlain
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

Review 7.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

Authors:  Winward Choy; Won Kim; Daniel Nagasawa; Stephanie Stramotas; Andrew Yew; Quinton Gopen; Andrew T Parsa; Isaac Yang
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

8.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 9.  Molecular genetics of meningiomas: from basic research to potential clinical applications.

Authors:  Matthias Simon; Jan P Boström; Christian Hartmann
Journal:  Neurosurgery       Date:  2007-05       Impact factor: 4.654

10.  Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.

Authors:  Marc C Chamberlain; Michael J Glantz; Camilo E Fadul
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910
View more
  3 in total

1.  HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.

Authors:  Arin N Graner; Justin E Hellwinkel; Alex M Lencioni; Helen J Madsen; Tessa A Harland; Paul Marchando; Ger J Nguyen; Mary Wang; Laura M Russell; Lynne T Bemis; Thomas J Anchordoquy; Michael W Graner
Journal:  Int J Hyperthermia       Date:  2016-12-20       Impact factor: 3.914

2.  Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.

Authors:  Muhammad O Chohan; Christopher T Ryan; Ranjodh Singh; Ryan M Lanning; Anne S Reiner; Marc K Rosenblum; Viviane Tabar; Philip H Gutin
Journal:  Neurosurgery       Date:  2018-06-01       Impact factor: 4.654

3.  Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo.

Authors:  Hiroyuki Takeda; Masashi Okada; Kenta Kuramoto; Shuhei Suzuki; Hirotsugu Sakaki; Tomomi Sanomachi; Shizuka Seino; Takashi Yoshioka; Hirofumi Hirano; Kazunori Arita; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2017-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.